PH24467A - Synergistics interplay of lymphokines and dsrnas - Google Patents

Synergistics interplay of lymphokines and dsrnas

Info

Publication number
PH24467A
PH24467A PH36569A PH36569A PH24467A PH 24467 A PH24467 A PH 24467A PH 36569 A PH36569 A PH 36569A PH 36569 A PH36569 A PH 36569A PH 24467 A PH24467 A PH 24467A
Authority
PH
Philippines
Prior art keywords
lymphokines
dsrnas
dsrna
human
interplay
Prior art date
Application number
PH36569A
Other languages
English (en)
Inventor
William A Carter
Original Assignee
Hem Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Res Inc filed Critical Hem Res Inc
Publication of PH24467A publication Critical patent/PH24467A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
PH36569A 1987-03-03 1988-02-29 Synergistics interplay of lymphokines and dsrnas PH24467A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2136887A 1987-03-03 1987-03-03

Publications (1)

Publication Number Publication Date
PH24467A true PH24467A (en) 1990-07-18

Family

ID=21803798

Family Applications (1)

Application Number Title Priority Date Filing Date
PH36569A PH24467A (en) 1987-03-03 1988-02-29 Synergistics interplay of lymphokines and dsrnas

Country Status (19)

Country Link
EP (1) EP0281380B1 (fr)
JP (1) JPH0713024B2 (fr)
KR (1) KR960008009B1 (fr)
CN (1) CN1054509C (fr)
AT (1) ATE130760T1 (fr)
AU (2) AU1256588A (fr)
CA (1) CA1336810C (fr)
DE (1) DE3854726T2 (fr)
DK (1) DK113188A (fr)
ES (1) ES2082749T3 (fr)
FI (1) FI880961L (fr)
IE (1) IE75895B1 (fr)
IL (1) IL85603A (fr)
NO (1) NO880946L (fr)
NZ (1) NZ223720A (fr)
PH (1) PH24467A (fr)
PT (1) PT86879B (fr)
RU (1) RU1836103C (fr)
ZA (1) ZA881512B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA881639B (en) * 1987-03-23 1989-02-22 Hem Res Inc Treatment of human viral infection by dsrna combined with viral inhibitors
ES2076259T3 (es) * 1989-06-30 1995-11-01 American Cyanamid Co Metodo para el tratamiento de enfermedades infecciosas activando celulas fagociticas en animales.
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
AR013269A1 (es) * 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
KR20010042069A (ko) 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
EP2314700A1 (fr) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition et méthode destinées à l'attenuation in vivo et in vitro de l'expression génique utilisant de l'ARN double brin
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2006054129A1 (fr) 2004-11-19 2006-05-26 Institut Gustave Roussy Traitement ameliore du cancer par arn double brin
EP2116602A1 (fr) 2008-05-07 2009-11-11 Institut Gustave Roussy Combinaison de produits pour traiter le cancer
CA2792258A1 (fr) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Compositions de cellules dendritiques induites et utilisations associees
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells
CA1326450C (fr) * 1985-08-26 1994-01-25 William A. Carter Modulation des manifestations associees au virus du sida au moyen d'arn a double brin

Also Published As

Publication number Publication date
KR960008009B1 (ko) 1996-06-19
IE75895B1 (en) 1997-09-24
EP0281380A2 (fr) 1988-09-07
NZ223720A (en) 1991-07-26
DK113188A (da) 1988-09-04
ES2082749T3 (es) 1996-04-01
DK113188D0 (da) 1988-03-02
EP0281380B1 (fr) 1995-11-29
PT86879A (pt) 1988-04-01
EP0281380A3 (en) 1989-09-27
CA1336810C (fr) 1995-08-29
IE880588L (en) 1988-09-03
ATE130760T1 (de) 1995-12-15
IL85603A (en) 1993-05-13
KR880010776A (ko) 1988-10-24
FI880961A7 (fi) 1988-09-04
NO880946D0 (no) 1988-03-03
IL85603A0 (en) 1988-08-31
JPH0713024B2 (ja) 1995-02-15
FI880961L (fi) 1988-09-04
PT86879B (pt) 1992-05-29
RU1836103C (ru) 1993-08-23
CN1054509C (zh) 2000-07-19
FI880961A0 (fi) 1988-03-02
CN1032296A (zh) 1989-04-12
NO880946L (no) 1988-09-05
AU1618992A (en) 1992-08-06
AU1256588A (en) 1988-09-01
JPS63295514A (ja) 1988-12-01
DE3854726D1 (de) 1996-01-11
ZA881512B (en) 1988-11-30
DE3854726T2 (de) 1996-07-25

Similar Documents

Publication Publication Date Title
EP0281380A3 (en) Synergistic interplay of lymphokines and dsrnas
NZ226005A (en) Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof
EP0238657A4 (fr) Agent immunotherapeutique antiviral et sa preparation.
PH23333A (en) Treatment of human viral infections by dsrna combined with viral inhibitors
IL78553A (en) Therapeutic compositions of phosphonylmethoxyalkyl adenines
EP0308197A3 (fr) Méthode pour stimuler le système immunitaire
ES2036526T3 (es) Composiciones de interferon.
HUT65404A (en) Protection from shock subsequent to injury by double-stranded rnas
EP0325018A3 (fr) RNase L inhibiteur comme marqueur pour des infections virales
DE69106877D1 (de) Aus blaualgen hergestellte biologisch aktive verbindungen.
EP0248583A3 (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
EP1013763A4 (fr) INTERLEUKINE 18 CANINE, INTERLEUKINE-1 $g(b)-CONVERTASE CANINE, SEQUENCES D'ADN CODANT CETTE ENZYME, PROCEDE DE PRODUCTION DE L'INTERLEUKINE 18, ET REMEDES CONTRE LES MALADIES IMMUNOLOGIQUES CHEZ LE CHIEN
Kohl Additive effects of acyclovir and immune transfer in neonatal herpes simplex virus infection in mice
EP0668771A4 (fr) Traitement des maladies autoimmunes par induction d'une tolerance des cellules, des tissus et des organes.
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.
Boonprakong Immune modulation with IL-2 and IL-12
ES2007094A6 (es) Procedimiento para la preparacion de 3 -c- ciano-2,3 -didesoxinucleosido.
ZA881639B (en) Treatment of human viral infection by dsrna combined with viral inhibitors